| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Octreotide | FAERS: 3 | US FAERS | |
| 2 | carbidopa, levodopa drug combination | FAERS: 2 | US FAERS | |
| 3 | Bosentan | FAERS: 1 | US FAERS | |
| 4 | Cabozantinib S-malate | FAERS: 1 | US FAERS | |
| 5 | Lacosamide | FAERS: 1 | US FAERS | |
| 6 | MDV 3100 | FAERS: 1 | US FAERS | |
| 7 | Ranitidine | FAERS: 1 | US FAERS | |
| 8 | Rifaximin | FAERS: 1 | US FAERS | |
| 9 | Tetrabenazine | FAERS: 1 | US FAERS | |
| 10 | Vigabatrin | FAERS: 1 | US FAERS | |
| 11 | glycerol phenylbutyrate | FAERS: 1 | US FAERS | |
| 12 | olaparib | FAERS: 1 | US FAERS | |
| 13 | rucaparib | FAERS: 1 | US FAERS | |
| 14 | treprostinil | FAERS: 1 | US FAERS |
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120329
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.